2137 EXPRESSION OF ESTROGEN RELATED PROTEINS IN HORMONE-REFRACTORY PROSTATE CANCER: ASSOCIATION WITH TUMOR PROGRESSION

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 20102137 EXPRESSION OF ESTROGEN RELATED PROTEINS IN HORMONE-REFRACTORY PROSTATE CANCER: ASSOCIATION WITH TUMOR PROGRESSION Olivier Celhay, Mokrane Yacoub, Bertrand Doré, Jacques Irani, Olivier Cussenot, and Gaëlle Fromont Olivier CelhayOlivier Celhay Poitiers, France More articles by this author , Mokrane YacoubMokrane Yacoub Poitiers, France More articles by this author , Bertrand DoréBertrand Doré Poitiers, France More articles by this author , Jacques IraniJacques Irani Poitiers, France More articles by this author , Olivier CussenotOlivier Cussenot Paris, France More articles by this author , and Gaëlle FromontGaëlle Fromont Poitiers, France More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2225AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prior in vitro studies demonstrated that estrogen may be implicated in genesis and progression of prostate cancer, but less is known about the expression of estrogen related proteins in hormone refractory prostate cancer. The aim of the study was to compare the expression of estrogen related proteins in patients with matched hormone-naive and refractory tumor pairs. METHODS Among 323 patients with prostate cancer treated at our institution between 1988 and 2008 with only hormonal therapy, 55 cases displayed available tissue samples collected both before treatment induction and after hormonal relapse. Hormonal relapse was defined following EAU guidelines. Using Tissue Micro-Array and immunochemistry, we analysed the expression of estrogen receptor alpha (ERA) and beta (ERB), BCAR1, Ki67 and aromatase. Proportions and continuous variables were analysed using Wilcoxon and Friedman paired tests respectively. The association between gene expression, time to hormonal relapse and overall survival was performed using Log-rank and Cox tests. RESULTS Ki67 (p<0.001) and BCAR1 (p=0.033) expressions were significantly increased after hormonal relapse, whereas ERB (p=0.016) and aromatase (p<0.001) expressions were significantly decreased. Median time to hormonal relapse was 21.7 months (7.6-67.1). High expression of aromatase (p=0.028; 3.71; 1.15-11.93) and low expression of ERA (p=0.026; 5.13; 1.22-21.62) were independent predictive factors of a shorter time to hormonal relapse. Median overall survival was 11.6 months (0.0-85.6). High expression of Ki67 (p=0.019; 1.16; 1.03-1.31) and low expression of ERA (p=0.013; 0.90; 0.83-0.98) were indepedent predictive factors of poor overall survival. CONCLUSIONS Our results suggest that estrogen metabolism may be implicated in the transition from hormone-naive to hormone refractory prostate cancer. High expression of ERA by the tumor microenvironment was a protective factor as regard to overall survival and the time to hormonal relapse. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e830-e831 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Olivier Celhay Poitiers, France More articles by this author Mokrane Yacoub Poitiers, France More articles by this author Bertrand Doré Poitiers, France More articles by this author Jacques Irani Poitiers, France More articles by this author Olivier Cussenot Paris, France More articles by this author Gaëlle Fromont Poitiers, France More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...